Novilytic
West Lafayette
About Novilytic
Monitoring the quality of lifesaving medicines is Novilytic’s mission. We accomplish this via the disruptive use of nanotechnology and cutting-edge science designed for Process R&D and pharmaceutical manufacturing. The Proteometer (Proteoform Meter) is a technology for drug development companies that can provide near-real-time warnings on molecular structure changes. Like a canary in an old coal mine, the Proteometer serves as our “Canary in the Fermentor.” This technology will be sold in the form of kits that allow customers to convert their LCs into a Proteometer in a short period of time. Training and service all remain the same, including one’s own software, thus ensuring ease of use and speed of adoption. Commercialization efforts are underway as the organization is preparing for an early 2023 product launch. -- Novilytic is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. Our talented team includes 5 Ph.D. chemists and engineers who have helped us secure significant patents and other IP.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.3M
- Last round: Undisclosed (Dec 2025)
- Website: novilytic.com
- Phone: 765-340-7140
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/novilytic-5349 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.